Moderna, Inc.
当前追踪的 33 家顶级对冲基金 2026 Q3 13F 申报中暂无重仓该标的记录
渗透率: 0.0%
-
💡 口径说明:变动幅度超过 ±0.5% 计为加仓增持/减仓减持,±0.5% 以内计为持仓不变;净增持占比 = (增持家数 + 新建仓家数) / 持仓机构总数。
基于 2026 Q3 SEC 13F 申报
🚀MRNA SGDC 量化评级与战术档案
📌 核心业务与护城河简评:Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
截至 2026-11-18 收盘,股价处于 50SMA 均线下方修正期(收盘结算价 $196.79 < 50SMA $205.61),触发动量风控拦截。
📈近 8 个季度机构持股演变趋势
追踪该标的在过去 8 个季度中被全球顶尖百亿基金持有数量与平均权重的历史变迁
🏛️持有该股的顶级机构明细2026 Q3
查看 2026 Q3 重仓该股的每家对冲基金经理、持股数量、仓位权重与调仓动向
| 投资大佬 / 机构 | 基金管理规模 | 持仓权重 | 持有股数 | 季度动向 | 操作 |
|---|---|---|---|---|---|
| 当前暂无顶级对冲基金持有该标的 | |||||
想知道华尔街大佬们本期最抱团的前 50 只暗牌金股?
与其单只股票反查,不如直接在共识筛股器中获取 33 家对冲基金共同重仓的 Alpha 清单。